Schneiderman Daniel H 4
4 · AzurRx BioPharma, Inc. · Filed Jan 9, 2020
Insider Transaction Report
Form 4
Schneiderman Daniel H
CHIEF FINANCIAL OFFICER
Transactions
- Award
Options
2020-01-02+335,006→ 335,006 totalExercise: $1.03Exp: 2030-01-02→ Common Stock (335,006 underlying)
Footnotes (1)
- [F1]Options granted in connection with the Reporting Person's appointment as Chief Financial Officer of the Issuer. The options will vest in three equal annual installments commencing on the first anniversary of the grant date, becoming fully vested on January 2, 2023.